MedPage Today (5/25, Monaco) reports, “The COVID-19 pandemic spurred” clinicians “to get creative in their shift to telepsychiatry for patients with schizophrenia, a subanalysis of the OASIS study” revealed. In fact, “across all types of visits – from routine to crisis visits – the percentage conducted via telepsychiatry increased more than threefold during the pandemic among 35 sites across the country,” researchers concluded.
Healio (5/25, Hemphill) reports, “According to the study, 94% of the investigators said telepsychiatry maintained the standard of care for patients with schizophrenia who are being treated with” long-acting injectables (LAIs). The findings were presented at the American Psychiatric Association 2022 Annual Meeting.
Related Links:
— MedPage Today (requires login and subscription)